By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Reata Pharmaceuticals, Inc. 

1950 Stemmons Freeway, Suite 5001

Dallas  Texas  75207  U.S.A.
Phone: 214-800-8700 Fax: 214-722-0867



Company News
Reata Pharmaceuticals, Inc. Announces Requested Withdrawal Of Registration Statement Due To Adverse Market Conditions 12/12/2016 7:56:21 AM
Reata Pharmaceuticals, Inc. Announces Filing Of Registration Statement For Proposed Public Offering 12/6/2016 7:53:11 AM
Reata Pharmaceuticals, Inc. Announces Plan for Global Phase II/III Trial in Chronic Kidney Disease Caused by Alport Syndrome 11/14/2016 7:46:56 AM
Reata Pharmaceuticals, Inc. Appoints Dawn Carter Bir As Vice President And Chief Commercial Officer 10/11/2016 7:26:55 AM
Reata Pharmaceuticals, Inc. Announces Interim Data From Extension Phase II LARIAT Study In Pulmonary Arterial Hypertension 6/23/2016 7:52:05 AM
Abbott Laboratories (ABT), Reata Pharmaceuticals, Inc. Kidney Disease Drug Trial Stopped 10/18/2012 9:42:10 AM
Reata Pharmaceuticals, Inc. to Present at 30th Annual J.P. Morgan Healthcare Conference 1/6/2012 11:13:10 AM
Reata Pharmaceuticals, Inc. Release: New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System 11/29/2011 11:52:45 AM
Reata Pharmaceuticals, Inc. Adds Executives to Management Team and Board of Directors 10/17/2011 10:46:12 AM
Reata Pharmaceuticals, Inc. and Abbott Laboratories (ABT) Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes 6/16/2011 9:08:28 AM